TPD Drug Targeted Performance Proteomics Analysis
With the rapid development of biotechnology, drug research and development has gradually entered a new era of precision and personalization. Targeted Protein Degradation (TPD) drugs are an emerging therapeutic strategy that can achieve precise treatment by utilizing the ubiquitin-proteasome system to degrade specific pathological proteins in the body. As an important new class of therapeutic drugs, TPD drugs are attracting increasing attention and innovation. The design of drugs targeting specific disease targets (TPD) has become a hot topic in the field of drug development.
Proteomics, as the science of studying the composition, structure, function, and interactions of proteins in organisms, can comprehensively reveal the interactions between drugs and proteins. By combining proteomics technology, we can deeply explore the targeting performance of TPD drugs, providing important evidence for the optimization and clinical application of drugs.
BaiTai Parker Biotechnology (BTP) has established a TPD drug targeting performance proteomics analysis platform using Thermo's Obitrap Fusion Lumos high-resolution mass spectrometer, providing you with TPD drug targeted degradation characteristic analysis services based on full proteomics technology. A single experiment can identify 8000-10000 full proteins. Our analysis services include but are not limited to:
• Target protein degradation activity(Target protein degradation activity)Analysis:
Using Data Independent Acquisition (DIA) technology and professional protein search software, it covers the proteome more comprehensively compared to traditional DDA technology represented by TMT/iTRAQ labeling quantification technology, while effectively improving the quantitative accuracy of the target protein (Protein of Interest, POI);
• Target selectivity (Target selectivity) analysis:
Through differential proteome analysis of POI and other differential protein changes, comprehensively evaluate the target selectivity of TPD drugs;
• Potential off-target and safety concerns (Potential off-target and safety concerns) analysis:
Based on the target selectivity results of TPD drugs, integrate multi-platform database analysis to explore the potential off-target risks and safety concerns of TPD drugs;
• Biological functions and mechanisms of action (Biological functions and mechanisms of action) analysis:
Using classical bioinformatics functional analysis strategies, such as PPI, GO, and KEGG, to explore the biological functions and mechanisms of action mediated by TPD drugs.
Experimental design and process
• Sample preparation: Reasonable concentration and time point experimental design;
• Sample pre-processing: Total protein extraction, proteolysis;
• Mass spectrometry acquisition: DIA acquisition, DIANN database search;
• Data processing: Automated analysis process, personalized analysis process.
Figure 1. TPD drug targeting performance proteomics analysis experimental process
Applicable sample types
• Cell pellet: At least 1 treatment group and 1 control group per group, with at least 3 samples recommended per group;
• Tissue samples: At least 1 treatment group and 1 control group per group, with at least 5 samples recommended per group.
Result delivery
TPD drug targeting performance proteomics analysisOne-stop service
You only need to place an order - send samples
BaiTai Parker Biotechnology one-stop service completion: Sample processing - On-machine analysis - Data analysis - Project report
Related services
How to order?
